ASX Announcement JD Health Strategic Agreement targeting $100m in Sales 18 November 2026, Beijing, China. Xenitra Limited (ASX:XEN) (Xenitra or the Company) is pleased to announce that Hong Kong Fukang Trading Co., Limited (Fukang), Xenitra’s pharmaceutical licensing and operating arm, through...
JD Health Strategic Agreement targeting $100m in Sales
Filed with ASX · · 4 pages · English
Summary by 6ix AI
Xenitra Limited has announced a Strategic Cooperation Agreement with JD Health, targeting significant sales over three years for various pharmaceutical products, including prescription and over-the-counter medicines. This agreement represents a major strategic move into higher-margin products and is expected to enhance Xenitra's market presence in China's pharmaceutical sector. The partnership aims to leverage Xenitra's existing distribution channels and expertise to achieve the sales target.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Earlier from Xenitra
- Investor Presentation - November 2026
- Quarterly Activities/Appendix 4C Cash Flow Report
- Notification of cessation of securities - XEN
- Notice of Annual General Meeting/Proxy Form
- Quoted Option Expiry
Follow Xenitra into a list and get an email when it puts out news.
Follow Xenitra